0001562762-22-000117.txt : 20220304 0001562762-22-000117.hdr.sgml : 20220304 20220304171341 ACCESSION NUMBER: 0001562762-22-000117 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220304 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220304 DATE AS OF CHANGE: 20220304 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GLOBUS MEDICAL INC CENTRAL INDEX KEY: 0001237831 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043744954 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35621 FILM NUMBER: 22715203 BUSINESS ADDRESS: STREET 1: 2560 GENERAL ARMISTEAD AVENUE CITY: AUDUBON STATE: PA ZIP: 19403 BUSINESS PHONE: 610-930-1800 MAIL ADDRESS: STREET 1: 2560 GENERAL ARMISTEAD AVENUE CITY: AUDUBON STATE: PA ZIP: 19403 8-K 1 gmed-20220304x8k.htm 8-K gmed-20220304x8k
false0001237831DE00012378312022-03-042022-03-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  March 4, 2022  

GLOBUS MEDICAL, INC.

(Exact name of registrant as specified in charter)

DELAWARE

 

001-35621

 

04-3744954

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403

(Address of principal executive offices) (Zip Code)

(610) 930-1800

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbols

Name of exchange on which registered

Class A Common Stock, par value $.001 per share

GMED

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 8.01 Other Events.

On March 4, 2022, Globus Medical, Inc. issued a news release announcing the expansion of its share repurchase program of the Company’s Class A common stock by an additional $200 million. A copy of the news release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.

Description

 

 

99.1

Press Release dated March 4, 2022

104

The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLOBUS MEDICAL, INC.

 

 

(Registrant)

 

 

 

Dated:

March 4, 2022

/s/ KEITH PFEIL

 

 

 

 

 

Keith Pfeil

Senior Vice President

 

 

Chief Financial Officer

EX-99.1 2 gmed-20220304xex99_1.htm EX-99.1 Exhibit 991 Stock Repurchase

Exhibit 99.1





Globus Medical Announces the Expansion of its Share Repurchase Program



AUDUBON, PA, March 4, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has expanded the Company’s share repurchase program by authorizing the repurchase of an additional $200 million of the Company’s common stock.  The new authorization, plus the approximate $95.3 million currently available under its existing share repurchase program, approved in March 2020, provides the Company with over $295 million available for future share repurchases.



“Our announcement today reflects the continued confidence that we have in our long-term growth profile and underlying earnings strength,” noted David Paul, Executive Chairman.  “We continue to view Globus as an attractive investment opportunity over the long-term and our strong balance sheet provides us with the financial flexibility to drive continued strategic investments, both organic and inorganic, while also providing returns to our shareholders through this share repurchase program.”



The timing and actual number of shares repurchased will be determined by management at its discretion and will depend on a variety of factors, including market price of the shares, general business and market conditions, applicable legal requirements, and alternative investment opportunities.  The repurchase program will be executed consistent with the company’s capital allocation strategy of prioritizing investment to grow the business over the long term. 



Repurchases may be made through privately negotiated transactions or open market transactions, including pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18 under the Securities Exchange Act of 1934, as amended.  The repurchase program has no time limit and may be suspended for periods or discontinued at any time.  The Company intends to utilize its cash reserves to fund the share repurchase program.



About Globus Medical, Inc.



Based in Audubon, Pennsylvania, Globus Medical, Inc. was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com. 



Safe Harbor Statements



All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms.  These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends.  Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted.  These risks and uncertainties include, but are not limited to, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks.  For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission.  These documents are available at www.sec.gov.   Moreover, we operate in an evolving environment.  New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements.  Forward-looking statements contained in this press release speak only as of the date of this press release.  We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:

Brian Kearns

Senior Vice President, Business Development and Investor Relations

Phone: (610) 930-1800

Email:  investors@globusmedical.com


 

www.globusmedical.com


EX-101.SCH 3 gmed-20220304.xsd EX-101.SCH 00090 - Document - Document and Entity Informationlink:presentationLinklink:calculationLinklink:definitionLink EX-101.LAB 4 gmed-20220304_lab.xml EX-101.LAB EX-101.PRE 5 gmed-20220304_pre.xml EX-101.PRE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Mar. 04, 2022
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Mar. 04, 2022
Entity Registrant Name GLOBUS MEDICAL, INC.
Entity Emerging Growth Company false
Title of 12(b) Security Class A Common Stock, par value $.001 per share
Trading Symbol GMED
Security Exchange Name NYSE
Entity File Number 001-35621
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 04-3744954
Entity Address, Address Line One 2560 GENERAL ARMISTEAD AVENUE
Entity Address, City or Town AUDUBON
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19403
City Area Code 610
Local Phone Number 930-1800
Amendment Flag false
Entity Central Index Key 0001237831
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 7 gmed-20220304x8k_htm.xml IDEA: XBRL DOCUMENT 0001237831 2022-03-04 2022-03-04 false 0001237831 DE 8-K 2022-03-04 GLOBUS MEDICAL, INC. 001-35621 04-3744954 2560 GENERAL ARMISTEAD AVENUE AUDUBON PA 19403 610 930-1800 false false false false Class A Common Stock, par value $.001 per share GMED NYSE false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +2)9%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "TB614%37C/.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)TU$,'1[43PI""XHWD(RNQMLFI",M/OVIG6WB^@#>,S,GV^^ M@6E-5"8D?$XA8B*'^6KR_9"5B1MV((H*()L#>IWKDAA*2UU2>:0]1FP^] M1Q")SZ%BZ &4:8?/XNH%V)2_5/[-(!=DI.V:VI<1SK42ZYLD,#;T^/+\NZE1LR MZ<%@^96=HF/$#3M/?I5W]]L'U@DN1,5EQ:^W0JA&*GG[/KO^\+L(^V#=SOUC MX[-@U\*ON^B^ %!+ P04 " "TB614F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M +2)9%2&PO=V]R:W-H965T&UL MG9A=<^(V%(:OM[]"P_2BG2'Q!X:0'<*, VS*;$*8D.Q.V^F%L 5H8DM>20[A MW_?($)NVYICI36S9/J\>'8GW2!ELI7K5&\8,>4\3H6]:&V.RSXZCHPU+J;Z4 M&1/P9B552@TTU=K1F6(T+H+2Q/%=M^>DE(O6<% \FZOA0.8FX8+-%=%YFE*U MNV6)W-ZTO-;'@R>^WAC[P!D.,KIF"V9>LKF"EE.JQ#QE0G,IB&*KFU;H?;[U M QM0?/&-LZT^NB=V*$LI7VUC&M^T7$O$$A89*T'A\L9&+$FL$G#\.(BVRCYM MX/']A_J78O PF"75;"23[SPVFYM6OT5BMJ)Y8I[D]C=V&%#7ZD4RT<5?LMU_ M&P0M$N7:R/00# 0I%_LK?3\DXCB@?R+ /P3X!?>^HX)R3 T=#I3<$F6_!C5[ M4PRUB 8X+NRL+(R"MQSBS' LHQR2; @5,9D(P\V.3,5^MB%K \= )_93)SH( MWNX%_1."#U1=$C=H$]_U_7^&.\!6 OHEH%_H=?X?(/DS7&JC8'+_0CKKE)UU MBLZ"ILZ>=QFK&SL>WK_XBD $)41P'L2<*2[MH&,"OBS(PV0\'87W;3*=C2X1O%Z)USL' M;Y(RM>9B3>X@WFS(2*89%;LZ3%QO11/-$*ZKDNL*U7GF)F%$KHCG_[+\E2Q8 ME"L K0/"A48)U9J$=D0IK/V%D=%KFV14D3>:Y(S\?.FZ'LD8V.Z&*@R]7Z+W M<71%8YO*Q2Y=RJ2.&(^_@SE&,*Y+C&M4YB-E9/(>;:A8LY,+#]>9_;Z8(#B> M6]FF>\Y2^\)A8F=YNF2JUBIQ$9BLBTZWYWL8TI&3>^<@344D529588]M6"-@ M'40J6#.Y,&H'U[@V<0WJ8S1OE9M[_CF0S_2=3&,P.;[BT=[(D2SBDFYPT;D* M@NMN@!%6)<##3?Q &,:Q8EJW/V[(/7Q''D5][G!)O]MSR=UD-GD*[TGX]#!= M/$_",0F_368O:%JKDN'A3O]OZ)%MP:0_RVU]#"*WG7@=C"VJF1X M#59?D,%&^S0*+M#S7 RD*@ >[N#W,H*QVUYKMA%!.EA8$+[73^L*]@[/:Y6]8N\0:^1K+)S'_??_Y!- MM, IO] -ZOI#0?#7M,+?_+,/P;4$L#!!0 ( +2)9%2?H!OPL0( .(, M - >&PO9KEMWDOSAR+DCO9*Z MW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MU MIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$ M>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5 M=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T M08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+ M?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!. MZ%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^& M^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA M>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7J MEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N- MY0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( +2) M9%27BKL

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports gmed-20220304x8k.htm gmed-20220304.xsd gmed-20220304_lab.xml gmed-20220304_pre.xml gmed-20220304xex99_1.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "gmed-20220304x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "gmed-20220304x8k.htm" ] }, "labelLink": { "local": [ "gmed-20220304_lab.xml" ] }, "presentationLink": { "local": [ "gmed-20220304_pre.xml" ] }, "schema": { "local": [ "gmed-20220304.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gmed", "nsuri": "http://www.globusmedical.com/20220304", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "gmed-20220304x8k.htm", "contextRef": "Duration_3_4_2022_To_3_4_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "gmed-20220304x8k.htm", "contextRef": "Duration_3_4_2022_To_3_4_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.globusmedical.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001562762-22-000117-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001562762-22-000117-xbrl.zip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end